Barclays analyst Geoff Meacham downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Equalweight to Underweight with a price target of $2.50 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE